Samsung Pharmaceutical삼성제약

Samsung Pharmaceutical remains loss-making on a trailing basis, with its share price down sharply over the past year.

Trailing twelve-month revenue to H1 2026 is about ₩42.7B, but operating income is roughly -₩16.3B and net income is roughly -₩137.2B, so the business is not currently profitable. The share price closed at ₩1,254 on 2026-10-27, down 17.7% over one year and well below its 52-week high of ₩2,320. Recent filings point to convertible bond and equity-linked activity and several management matters, but the data does not explain their purpose or impact.

What stands out

• Revenue was ₩46.1B in 2025 (up 4%) after falling in 2024, but operating losses have persisted every year from 2021 to H1 2026.
• Trailing net loss of about ₩137.2B is far larger than the operating loss, and the data does not explain the gap.
• Trailing free cash flow is about -₩9.8B, and borrowings of ₩14.4B exceed cash of ₩4.6B.
• The 2025 net income of ₩11.5B was positive despite an operating loss, which the data does not explain.
• Filings in Aug to Sep 2026 include convertible bond decisions, an own-bond acquisition, and several major management matters; news headlines were not available in the data.
• Foreign ownership is small at 2.9%, and recent 20-day flows were net foreign selling of about ₩80M.

What to watch

• The next quarterly or annual results, to see whether operating losses narrow and whether free cash flow turns positive.
• Details of the convertible bond issue and the major management matters filed in September 2026, which the data does not describe.
• Progress on the GV1001 development programmes named in the company profile; the data gives no clinical timeline.